Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PCI-32765CAN3001: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

NCT01804686 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT01804686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01804686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PCI-32765CAN3001: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 9, 2013
Completion date
December 31, 2029
Enrollment
539 (actual)
Sites
175

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft versus host disease, chronic lymphocytic leukemia, diffuse large b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, waldenstrom macroglobulinemia